Fund moves

Cencora (COR): Wedge Capital Management L L P reduced its stake -7,014 shares

Wedge Capital Management L L P reduced its stake in Cencora, per its Q4 2025 13F.

81K
Shares reported · -7,014 vs prior quarter
0.49%
Disclosed portfolio weight
$27.5M
Reported value
Holdings as of
Dec 31, 2025
Filed
Jan 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 18, 2025InsiderCEO sold ~$1.87M of COR shares in the open market
  2. Dec 17, 2025InsiderOfficer sold ~$1.38M of COR shares in the open market
  3. Dec 18, 2025InsiderCEO sold ~$1.75M of COR shares in the open market
  4. Dec 19, 2025Insider · 2 peopleInsiders: 2 sales (~$1.7M)
  5. Jan 12, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  6. Jan 14, 2026FDARecall: Oxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, The drug product contained in this package is from NDC…

What came next

  1. Jan 16, 2026Federal contract · $7.7M obligatedDepartment of Defense awarded Cencora: $7.74M obligated to date
  2. Jan 20, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On January 20, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Ellen G. Cooper to serve on the Board (the “Appointment”), effective immediately.”
  3. Jan 20, 2026Insider · 13 days before resultsCEO sold ~$1.81M of COR shares in the open market
  4. Feb 2, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  5. Feb 13, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  6. Feb 18, 2026Federal contract · $5.2M obligatedDepartment of Defense awarded Cencora: $5.18M obligated to date
  7. Feb 18, 2026Federal contract · $4.8M obligatedDepartment of Defense awarded Cencora: $4.79M obligated to date
  8. Feb 18, 2026InsiderCEO sold ~$479K of COR shares in the open market
  9. Feb 20, 2026InsiderCEO sold ~$1.35M of COR shares in the open market
  10. Mar 11, 2026Federal contract · $9.0M obligatedDepartment of Defense awarded Cencora: $9.01M obligated to date
  11. Mar 16, 2026FDARecall: Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Distributed…
  12. Mar 17, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026.”
  13. Mar 23, 2026Congress · 1 personMembers of Congress: 2 purchases
  14. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  15. Mar 31, 2026CongressDisclosed purchase of COR — reported range $1,001 - $15,000
  16. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.3%
  17. May 1, 2026FDARecall: Primidone Tablets, USP, 50 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217. Ca…
  18. May 1, 2026FDARecall: Primidone Tablets, USP, 250 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217. C…
  19. May 6, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Cencora

For Cencora, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COR page.

How this filing works

Explore the data

Common questions

What does this filing report about Cencora (COR) stock?

Wedge Capital Management L L P reduced its stake in Cencora, per its Q4 2025 13F. Now 81K shares, $27.5M reported value, 0.49% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2025. Filed: Jan 14, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Cencora recently?

For Cencora, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the COR page.

Does this mean COR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Cencora

Everything OQRO holds on this company is on its COR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data